
Sign up to save your podcasts
Or
After a long 18 months of living through a pandemic, vaccines have paved a way forward to a new normal – Just 6 weeks ago, the Pfizer vaccine received emergency use authorization for adolescents down to age 12; and here at Children’s Colorado, we are a Pfizer vaccine trial site for kids ages 5-11. As more of our pediatric patients become eligible for the vaccine, primary care providers will be considering how to safely vaccinate patients with a risk of allergic reaction. In this episode, we will talk about the incidence, suspected epidemiology and current policy related to allergic reactions to the SARS-CoV-2 vaccines and steps for avoiding potential adverse reactions.
Today's guest is Dr. Matt Greenhawt, Director of the Food Challenge and Research Unit at Children’s Hospital Colorado and Associate Professor of Pediatrics, Section of Allergy & Immunology at the University of Colorado School of Medicine.
Do you have thoughts about today's episode or suggestions for a future topic? Write to us, [email protected]
4.9
254254 ratings
After a long 18 months of living through a pandemic, vaccines have paved a way forward to a new normal – Just 6 weeks ago, the Pfizer vaccine received emergency use authorization for adolescents down to age 12; and here at Children’s Colorado, we are a Pfizer vaccine trial site for kids ages 5-11. As more of our pediatric patients become eligible for the vaccine, primary care providers will be considering how to safely vaccinate patients with a risk of allergic reaction. In this episode, we will talk about the incidence, suspected epidemiology and current policy related to allergic reactions to the SARS-CoV-2 vaccines and steps for avoiding potential adverse reactions.
Today's guest is Dr. Matt Greenhawt, Director of the Food Challenge and Research Unit at Children’s Hospital Colorado and Associate Professor of Pediatrics, Section of Allergy & Immunology at the University of Colorado School of Medicine.
Do you have thoughts about today's episode or suggestions for a future topic? Write to us, [email protected]
496 Listeners
707 Listeners
285 Listeners
124 Listeners
281 Listeners
253 Listeners
3,336 Listeners
1,095 Listeners
185 Listeners
519 Listeners
160 Listeners
1,475 Listeners
366 Listeners
226 Listeners
317 Listeners